New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
10:35 EDTLLYEli Lilly drops after cancer drug data seen as 'underwhelming'
Eli Lilly (LLY) is retreating after the company reported a median overall survival rate of 5.2 months for patients who received the company's gastric cancer treatment, ramucirumab, in an abstract posted last night on the American Society of Clinical Oncology’s website. Patients who received a placebo had a median overall survival rate of 3.8 months. Although the overall survival rate produced by the drug was statistically significant, Leerink Swann analyst Seamus Fernandez called the data "somewhat underwhelming" in a note to investors earlier today. The company may still seek FDA approval for ramucirumab, but the agency will likely require the company to conduct another study before it will approve the drug, the analyst believes. Fernandez maintained an Outperform rating on the stock, which slid $1.10 ,or 2.06%, to $52.34 in mid-morning trading.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:04 EDTLLYDenovo Biopharma licensed Pomaglumetad Methionil from Eli Lilly
Subscribe for More Information
07:16 EDTLLYCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
08:53 EDTLLYNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
February 24, 2015
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:06 EDTLLYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
February 19, 2015
08:04 EDTLLYEli Lilly extends Evacetrapib Phase 3 trial by six months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use